T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy-Reference-Cited by-同舟云学术

T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy

Published:2024-01-24 Issue:4 Volume:30 Page:984-989
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Ghilardi Guido,Fraietta Joseph A.^ORCID,Gerson James N.,Van Deerlin Vivianna M.^ORCID,Morrissette Jennifer J. D.,Caponetti Gabriel C.^ORCID,Paruzzo Luca,Harris Jaryse C.,Chong Elise A.^ORCID,Susanibar Adaniya Sandra P.^ORCID,Svoboda Jakub,Nasta Sunita D.,Ugwuanyi Ositadimma H.,Landsburg Daniel J.,Fardella Eugenio^ORCID,Waxman Adam J.,Chong Emeline R.^ORCID,Patel Vrutti,Pajarillo Raymone,Kulikovskaya Irina,Lieberman David B.,Cohen Adam D.^ORCID,Levine Bruce L.^ORCID,Stadtmauer Edward A.,Frey Noelle V.,Vogl Dan T.^ORCID,Hexner Elizabeth O.^ORCID,Barta Stefan K.,Porter David L.,Garfall Alfred L.,Schuster Stephen J.^ORCID,June Carl H.^ORCID,Ruella Marco^ORCID

Funder

U.S. Department of Health & Human Services | NIH | National Cancer Institute

Laffey-McHugh Foundation

Society for Immunotherapy of Cancer

Leukemia and Lymphoma Society

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41591-024-02826-w.pdf

Reference48 articles.

1. US FDA. FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-investigating-serious-risk-t-cell-malignancy-following-bcma-directed-or-cd19-directed-autologous (2023).

2. Thomas, A. et al. Second malignancies after multiple myeloma: from 1960s to 2010s. Blood 119, 2731–2737 (2012).

3. Travis, L. B. et al. Second cancers among long-term survivors of non-Hodgkin′s lymphoma. J. Natl Cancer Inst. 85, 1932–1937 (1993).

4. Sacchi, S. et al. Secondary malignancies after treatment for indolent non-Hodgkin′s lymphoma: a 16-year follow-up study. Haematologica 93, 398–404 (2008).

5. Kim, H. N. et al. Composite follicular lymphoma and classic Hodgkin lymphoma. J. Pathol. Transl. Med. 56, 57–60 (2022).

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CAR-T cells targeting CCR9 and CD1a for the treatment of T cell acute lymphoblastic leukemia;2024-09-03

2. Peripheral T-cell lymphoma: From biology to practice to the future;Cancer Treatment Reviews;2024-09

3. The Current Landscape of Secondary Malignancies after CAR T-Cell Therapies: How Could Malignancies Be Prevented?;International Journal of Molecular Sciences;2024-09-01

4. Tracking non-relapse mortality after CAR T cell therapy;Nature Medicine;2024-08-30

5. Harnessing the evolving CRISPR/Cas9 for precision oncology;Journal of Translational Medicine;2024-08-08